Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag add-on therapy in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension
2018-002823-41Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Selexipag + standard of care, Placebo + standard of care and Open-label selexipag extension (3 arms). Primary endpoint: Pulmonary vascular resistance at Week 20. Started Sep 2018; status: completed.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2018-002823-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002823-41.